After CEO-switching saga CureVac names full-time chief, CSO AbbVie cans Voyager Alzheimer’s, Parkinson’s gene therapy pacts Struggling Redx out-licenses fibrotic asset to AstraZeneca, sees stock sky rocket Merck bags J&J castoff from Hanmi to expand NASH pipeline PMV Pharma nabs $70M for tumor suppressor programs Pfizer reups PPD deal in a contract research pact spree Novartis’ Ilaris unexpectedly slashes need for joint replacements from osteoarthritis in key study NIH picks seven COVID-19 diagnostic tests in 'Shark Tank' competition, unlocking $248.7M in scale-up funding Featured Story | By Amirah Al Idrus Even as it scrambled to pitch in against the COVID-19 pandemic, CureVac found itself embroiled in a game of executive musical chairs. Now, as it pushes an mRNA vaccine toward the clinic, it’s named a permanent chief, Franz-Werner Haas, and signed a Novartis alum, Igor Splawski, Ph.D. as its new top scientist. read more |
| |
|---|
|
Top Stories By Nick Paul Taylor AbbVie has terminated its Alzheimer's and Parkinson’s disease pacts with Voyager Therapeutics. The Big Pharma paid $134 million to enter into the two partnerships, but then dropped the projects after Voyager completed research activities. read more By Ben Adams AstraZeneca is picking up a delayed preclinical fibrosis candidate from Redx in a deal that gives the U.K. biotech a much needed cash boost which also saw its shares sky rocket. read more By Nick Paul Taylor Merck is set to pay Hanmi Pharmaceutical $10 million for the rights to a GLP-1/glucagon dual receptor agonist that Johnson & Johnson discarded last year. J&J studied the drug in midphase obesity clinical trials, but Merck sees it as a potential treatment for nonalcoholic steatohepatitis (NASH). read more By Amirah Al Idrus PMV Pharmaceuticals is topping up its coffers—just eight months after raising $62 million in its series C round, the cancer biotech is reeling in another $70 million. The capital will advance a suite of candidates targeting p53, a tumor-suppressing protein that is mutated in many cancers. read more By Ben Adams Pfizer has always been a heavy user of CROs, and over the past few months it’s been ramping up its partnerships. read more By Arlene Weintraub Novartis has been laboring for the last few years to expand the market for Ilaris, a drug that’s currently approved to treat a few rare inflammatory diseases. Now it has data from a 10,000-patient trial showing that people with osteoarthritis taking the drug had 40% to 47% lower rates of total knee or hip replacements than did those taking a placebo. read more By Conor Hale After scrutinizing several dozen submissions to its national, “Shark Tank”-esque pitch competition for new COVID-19 diagnostics technologies, the National Institutes of Health has selected its first seven projects that will move on to a new phase of manufacturing and scale-up—and has unlocked nearly a quarter of a billion dollars for the effort. read more Enrollment Showcase | Presented by: Biotility Taught by experienced professionals, Biotility’s online short courses provide the knowledge and practical skills valued by the bioscience industry. Enhance your career through coursework in one of our certificate pathways, including Document Management, Operations Management, and Quality Management. Learn more. |
| |
|---|
|
Resources Sponsored by: Paysign Download the whitepaper for a solution designed to connect manufacturers, pharmacists, and patients. In this special guide, you will learn not just about the law but about the portal platform designed to change the entire process for all. Sponsored by: Catalent In a BioPharma Dive industry survey, planning and forecasting were identified as top concerns for trial sponsors. In response to this need, the CSM team at Catalent has developed a methodology for identifying, evaluating, and proactively managing the inherent risks involved in clinical trial supply chain management. Sponsored by: Lonza Pharma & Biotech A novel spray-dried dispersion platform has been developed to faciliate high drug load applications Sponsored by: Catalent Learn about a real-world example of how clinical supply management expertise was applied to overcome inventory challenges for a complex, global study. Sponsored by: Catalent Whether a study is simple or highly complex, forecasting and simulation reports serve as data driven communication tools to help minimize risks and keep the study on track. Learn more about forecasting solutions for informed decision making and supporting contingency planning for clinical study. Sponsored by: Catalent Learn how to drive excellence within the forecasting process and utilize forecasting throughout the clinical study to better plan clinical supply budgets and project timelines. Explore how to identify potential supply-related issues before they can negatively impact your study. 18th Annual Discovery on Target Virtual September 16-18, 2020 Drug Development Boot Camp® 2020 November 18-19, 2020 | Register now! Pre-Boot Camp training ongoing now. | COVID19 provisions – training will be on-site as normal. | New – may be possible for some individuals to access the training virtually in real time. |
